← back to search

David P. Ryan

University of New England · US
Area of research
Oncology · Cancer Research
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, and Gastric Cancer Management and Outcomes.
h-index
91
citations
35,381
works
930
NIH funding
primary concept
email

Recent publications

Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors.
2026cited by 0position: contributordoi
Data from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Supplementary Table 4 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Supplementary Table 3 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Supplementary Table 2 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Table 2 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Supplementary Table 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Supplementary Figure 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Table 3 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Table 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Figure 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Figure 2 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
2026cited by 0position: contributordoi
Academic Medical Centers and ASCO Recommendations: Starting a Difficult Discussion.
2025cited by 0position: contributordoi
To contrast or not to contrast? Evaluating the diagnostic accuracy of hepatobiliary contrast agents in liver FDG-PET/MR: a prospective study.
2025cited by 0position: contributordoi
Supplementary Figure S3 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025cited by 0position: contributordoi
Supplementary Table S2 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025cited by 0position: contributordoi
Supplementary Table S4 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025cited by 0position: contributordoi
Supplementary Figure S5 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025cited by 0position: contributordoi
Supplementary Methods and Figures from Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial–Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Ductal Adenocarcinoma
2025cited by 0position: contributordoi
Supplementary Figure S4 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025cited by 0position: contributordoi
Supplementary Table S1 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025cited by 0position: contributordoi
Supplemental Table 3: Pattern 7 Ordered Genes from Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial–Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Ductal Adenocarcinoma
2025cited by 0position: contributordoi
Supplementary Table S6 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025cited by 0position: contributordoi
Supplementary Figure S7 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025cited by 0position: contributordoi
Supplemental Table 1: Pancreas Gene Markers from Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial–Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Ductal Adenocarcinoma
2025cited by 0position: contributordoi
Supplementary Figure S1 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025cited by 0position: contributordoi
Supplementary Figure S2 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025cited by 0position: contributordoi
Supplemental Table 2: Pattern 1 Pathways from Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial–Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Ductal Adenocarcinoma
2025cited by 0position: contributordoi
Supplementary Figure S6 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025cited by 0position: contributordoi
Supplementary Table S5 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 84 papers (2023–2026)Jeffrey W. Clark · Chris O’Brien Lifehouse82 papers (2023–2026)Theodore S. Hong · Harvard University78 papers (2014–2025)Carlos Fernández‐del Castillo · Harvard University73 papers (2014–2025) · 69 papers (2023–2025)Heena Kumra · Harvard University69 papers (2023–2025)Dan G. Duda · Marion General Hospital69 papers (2023–2025)Rakesh K. Jain · The University of Texas of the Permian Basin69 papers (2023–2025) · 69 papers (2023–2025)Jennifer Wo · Brigham and Women's Hospital69 papers (2023–2025)Yves Boucher · Harvard University69 papers (2023–2025)Mikael J. Pittet · Agora69 papers (2023–2025)Spencer R. Rosario · Cancer Genetics (United States)69 papers (2023–2025) · 69 papers (2023–2025)Jessica M. Posada · Memorial Sloan Kettering Cancer Center69 papers (2023–2025)Mari Mino-Kenudson · Boston University69 papers (2023–2025)Dai Fukumura · Brigham and Women's Hospital69 papers (2023–2025)Nilesh Talele · Harvard Stem Cell Institute69 papers (2023–2025)Liqun Gu · University of Missouri69 papers (2023–2025)Ashwin S. Kumar · Stanford University69 papers (2023–2025)